• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.

作者信息

Kantarjian Hagop M

机构信息

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leukemia. 2023 Nov;37(11):2324-2325. doi: 10.1038/s41375-023-02053-1. Epub 2023 Oct 5.

DOI:10.1038/s41375-023-02053-1
PMID:37798329
Abstract
摘要

相似文献

1
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.慢性髓性白血病未达到酪氨酸激酶抑制剂（TKI）治疗里程碑的影响是什么。
Leukemia. 2023 Nov;37(11):2324-2325. doi: 10.1038/s41375-023-02053-1. Epub 2023 Oct 5.
2
How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.慢性髓性白血病在治疗过程中未达治疗节点后如何实现个体化治疗：权衡慢性髓性白血病的延迟缓解和早期死亡与其他治疗方法的风险。
Leukemia. 2024 Feb;38(2):465-466. doi: 10.1038/s41375-024-02139-4. Epub 2024 Jan 13.
3
Survival with chronic myeloid leukaemia after failing milestones.失败里程碑后慢性髓性白血病的生存。
Leukemia. 2023 Nov;37(11):2231-2236. doi: 10.1038/s41375-023-02028-2. Epub 2023 Sep 19.
4
Exercise-induced release of cardiac and skeletal muscle injury biomarkers in patients with chronic myeloid leukemia receiving TKI therapy.接受酪氨酸激酶抑制剂（TKI）治疗的慢性髓性白血病患者运动诱导的心肌和骨骼肌损伤生物标志物释放
Blood Cancer J. 2023 May 30;13(1):90. doi: 10.1038/s41408-023-00861-3.
5
Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.酪氨酸激酶抑制剂时代加拿大慢性髓性白血病移植后的结局
Leuk Res. 2018 Oct;73:67-75. doi: 10.1016/j.leukres.2018.08.021. Epub 2018 Sep 5.
6
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.慢性髓性白血病慢性期早期分子反应对深度分子反应的预测价值
Medicine (Baltimore). 2019 Apr;98(15):e15222. doi: 10.1097/MD.0000000000015222.
7
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.酪氨酸激酶抑制剂治疗失败的 BCR-ABL 突变慢性髓性白血病患者的发生率和结局。
Cancer Med. 2019 Sep;8(11):5173-5182. doi: 10.1002/cam4.2410. Epub 2019 Jul 27.
8
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.E13A2 BCR-ABL 转录本会对接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的持续深度分子反应和无治疗缓解的实现产生负面影响。
Cancer. 2019 May 15;125(10):1674-1682. doi: 10.1002/cncr.31977. Epub 2019 Feb 1.
9
[Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].[慢性髓性白血病对酪氨酸激酶抑制剂耐药患者中与BCR-ABL激酶结构域突变相关的变量]
Zhonghua Xue Ye Xue Za Zhi. 2020 Jun 14;41(6):469-476. doi: 10.3760/cma.j.issn.0253-2727.2020.06.006.
10
[Experimental studies on etiology and pathogenesis of human chronic myeloid leukemia; chronic and experimental hyperleukocytosis and myelosis due to transmission of chronic human leukemia].人类慢性髓性白血病病因及发病机制的实验研究；慢性人类白血病传播所致的慢性及实验性白细胞增多症和骨髓增生症
Arch Med Exp. 1952;15(2):189-96.

本文引用的文献

1
Management of chronic myeloid leukemia in 2023 - common ground and common sense.2023 年慢性髓性白血病的管理——共识与常理。
Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9.
2
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor.酪氨酸激酶抑制剂治疗 2 年后仍未达到主要分子缓解的慢性髓性白血病。
Am J Hematol. 2023 Apr;98(4):639-644. doi: 10.1002/ajh.26836. Epub 2023 Jan 16.
3
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
酪氨酸激酶抑制剂停药后慢性髓性白血病患者无治疗缓解。
Am J Hematol. 2022 Jul;97(7):856-864. doi: 10.1002/ajh.26550. Epub 2022 Apr 7.
4
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.慢性髓性白血病临床实践指南（2021 年版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047.
5
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
6
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.伊马替尼作为慢性粒细胞白血病一线治疗的评估：随机CML研究IV的10年生存结果及非CML决定因素的影响
Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.
7
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.酪氨酸激酶抑制剂时代慢性期慢性髓性白血病患者的相对生存率：来自六项前瞻性临床试验的患者数据分析
Lancet Haematol. 2015 May;2(5):e186-93. doi: 10.1016/S2352-3026(15)00048-4. Epub 2015 Apr 20.
8
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.对于伊马替尼治疗 3 个月后 BCR-ABL1＞10%的 CML 患者，其预后取决于 BCR-ABL1 的下降速度。
Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23.
9
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.对于在 3 个月时没有主要细胞遗传学反应的慢性髓性白血病患者，可能需要在 6 个月时进行评估。
Haematologica. 2013 Nov;98(11):1686-8. doi: 10.3324/haematol.2013.090282. Epub 2013 Jun 28.
10
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.评估慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗 3 个月时的 BCR-ABL1 转录本水平是预测其预后的唯一要求。
J Clin Oncol. 2012 Jan 20;30(3):232-8. doi: 10.1200/JCO.2011.38.6565. Epub 2011 Nov 7.